Phase 4 Study of the Efficacy of Pentoxifylline in Patients With Chronic Kidney Disease Receiving Angiotensin Receptor Blockade
In patients with CKD and serum creatinine 1.3~6.0 md/gl, having taken losartan 100 mg/day
for at least 3 months, with stable renal function, will be recruited to a randomized
open-label trial. Patients taking pentoxifylline or not will be compared for their spot
urinary proteinuria, estimated glomerular filtration, spot urine tumor necrosis
factor-α/creatinine ratio, spot urine monocyte-chemoattractant protein-1/creatinine, and
aldosterone concentration between groups in a 2-year study. Add-on pentoxifylline in control
group in the same dose as in treat group will be performed to observe the renoprotective
effect if any protective potential is demonstrated in the end of maintenance 12 months.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
spot urinary proteinuria between groups
Tun-Jun Tsai, MD, PhD
Principal Investigator
National Taiwan University Hosptial
Taiwan: Department of Health
930202
NCT00155246
July 2004
January 2007
Name | Location |
---|